- What’s next for account management?
- OVID Health founder Jenny Ousbey discusses the pandemic, patient advocacy and the Patient Partnership Index
- Gilead’s Frances Luff considers how updating NICE’s cost appraisal process and its take on value could secure fairer access to innovative treatments in the UK
- Samantha Dawson details her experiences living with HIV
- Gilead Sciences’ global patient engagement lead and former HIV nurse specialist Geraldine Reilly explores today’s fight against the virus – as TV series It’s A Sin brings back memories of working on the frontline during the AIDS epidemic of the 1980s and 1990s
- Abbott’s Dr Nick West talks to PharmaTimes about going beyond intervention to improve the care of cardiovascular patients in the UK
- Taking a look at the recent dispute between the EU Commission and AstraZeneca over the ins and outs of its contract, Stuart Evans, commercial litigation expert and partner at law firm BLM, examines what this could represent for EU/UK cross-border pharma relations
- Digital health technologies are failing to reach their potential to boost the quality and efficiency of healthcare systems, largely because of a lack of dedicated access pathways or value assessment processes
- After an eventful year, what’s next for the UK’s life sciences sector? Dr Kath MacKay looks into three areas for development in the years ahead
- Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes some of the most important reforms for health and social care for nearly ten years
- The 2021 Clinical Researcher of the Year – The Americas competition is reaching out to the very best in the industry to take the next step and claim gold.
- Device designed to help clinicians detect lesions in the colon during a colonoscopy
- Sanofi could pay up to €414m for C4X Discovery’s oral IL-17A inhibitor programme
- Experimental drug plus immunotherapy demonstrated early potential in aggressive brain cancer
- Diabetes drug was unable to prevent all-cause mortality in Phase III study
- A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
- The combination is not considered to be a cost-effective use of NHS resources in this setting
- The drug was discovered through an AI-design platform within just eight months of project initiation
- The drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19
- The Cancer Research UK spinout is developing precision T cell therapies to treat multiple cancers
- American Journal of Clinical Oncology
- Diabetes Care
- The Oncologist
- Clinical Cardiology
- American Journal of Clinical Oncology
- The Federal Retail Pharmacy Program is expanding, which means more and more community pharmacists will begin providing one or more COVID-19 vaccines. Pharmacists preparing to deliver the world’s most coveted puncture can rely on advice from pharmacists […]
- The first patient to take a COVID-19 test at a Hartig Drug in Illinois approached the drive-thru window on foot. Homeless and not feeling well, he had been told by a local shelter that he would need […]
- Pharmacy-based point-of-care testing has long been available in many states, enabling pharmacists to monitor chronic conditions such as diabetes or high cholesterol. In recent months, though, legislation authorizing pharmacists to “test and treat” for selected minor, nonchronic […]
- Solution is available online at pharmacytoday.org.
- Depression is a common and serious mood disorder, with nearly 7% of U.S. adults reporting at least one episode of major depression in the past year. The common adverse effects associated with antidepressants cause many patients to […]
- Drug class: CD38-directed cytolytic antibody.
- Results from two studies published in the New England Journal of Medicine support the use of catheter cryoballoon ablation over antiarrhythmic therapy as initial therapy for patients with symptomatic, paroxysmal atrial fibrillation (AFib). The research was based […]
- Researchers have discovered a significant link between a reduction in death from COVID-19 with prior use of the diabetes drug metformin. In a study published in Frontiers in Endocrinology in January 2021, Shalev and colleagues found a […]
- Most pharmacists are “at will” employees, meaning that without an employment contract stating to the contrary, they can be discharged at the employer's will for any or no reason. Many state laws contain an exception to the […]
- When Raisa El-Kurdi, PharmD, CPP, started as a PGY1 community-based pharmacy resident at the Counseling and Psychological Services clinic at the University of North Carolina (UNC) at Chapel Hill, she would accompany the clinic psychiatrist during the […]
- The Ferris State University Doctorate in Community College Leadership National Advisory Board has established a scholarship endowment in recognition of Roberta Teahen of Traverse City for her extraordinary contributions to and leadership of the DCCL program.
- A low-cost clinical skills trainer, developed to assist Ferris State University Nursing students in their mastery of various manual patient care activities, moves from the prototype phase to unit production, with the help of an Innovation Grant from Ferris’ External and International Operations department.
- A year-round learning experience for individuals with learning disabilities begins at Ferris State University during the Fall 2021 semester. Grand Rapids-based Ready for Life plans to bring partnership and its curriculum to a third Michigan postsecondary education institution.
- A collaborative effort in Ferris State University’s College of Business is receiving support through a partnership with MindFire, Inc., an Irvine, California-based marketing communications firm.
- To further support student education at Ferris State University’s Michigan College of Optometry, CooperVision has donated funds to The Ferris Foundation to provide scholarships and training for myopia management.
East Paris Pharmacy
2060 E. Paris Ave Suite 102
Grand Rapids, MI, 49546
Email: eppharmacy102@gmail.com
Phone: 1 (616) 805-4601
Fax: 1 (616) 805-4826
S
